Akoya Biosciences (AKYA) Stock Price, News & Analysis

Company Overview

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Key Stats

• Today's Range: $2.08 to $2.29
• 50-Day Range: $2.09 to $3.24
• 52-Week Range: $1.88 to $6.31
• Volume: 119,917 shs
• Average Volume: 226,099 shs
• Market Capitalization: $107.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.43
• Consensus Rating: Hold

Akoya Biosciences Stock Analysis - MarketRank™

Akoya Biosciences scored higher than 34% of companies evaluated by MarketBeat, and ranked 777th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Akoya Biosciences has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 3 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Akoya Biosciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Akoya Biosciences are expected to grow in the coming year, from ($0.99) to ($0.53) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Akoya Biosciences is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Akoya Biosciences is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Akoya Biosciences has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.80% of the float of Akoya Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Akoya Biosciences has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Akoya Biosciences has recently decreased by 20.79%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Akoya Biosciences does not currently pay a dividend.

Dividend Growth

Akoya Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.80% of the float of Akoya Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Akoya Biosciences has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Akoya Biosciences has recently decreased by 20.79%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: -0.18

News Sentiment

Akoya Biosciences has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 21 news articles for Akoya Biosciences this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for AKYA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Akoya Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.30% of the stock of Akoya Biosciences is held by insiders.

Percentage Held by Institutions

79.42% of the stock of Akoya Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AKYA Stock Analysis - Frequently Asked Questions

How have AKYA shares performed this year?

Akoya Biosciences' stock was trading at $4.88 at the beginning of 2024. Since then, AKYA shares have decreased by 55.7% and is now trading at $2.16.
View the best growth stocks for 2024 here.

How were Akoya Biosciences' earnings last quarter?

Akoya Biosciences, Inc. (NASDAQ:AKYA) issued its quarterly earnings results on Monday, August, 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.27). The business earned $23.16 million during the quarter, compared to analysts' expectations of $23.61 million. Akoya Biosciences had a negative net margin of 66.77% and a negative trailing twelve-month return on equity of 162.99%.

When did Akoya Biosciences IPO?

Akoya Biosciences (AKYA) raised $125 million in an IPO on Friday, April 16th 2021. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity served as the underwriters for the IPO.

Who are Akoya Biosciences' major shareholders?

Top institutional investors of Akoya Biosciences include State Street Corp (0.92%), GSA Capital Partners LLP (0.63%), Charles Schwab Investment Management Inc. (0.13%) and Barclays PLC (0.08%). Insiders that own company stock include Matthew Winkler, Garry PhD Nolan, Brian Mckelligon, John Frederick Ek, Frederic Pla, Joseph Driscoll and Niro PhD Ramachandran.
View institutional ownership trends.

How do I buy shares of Akoya Biosciences?

Shares of AKYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Akoya Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Akoya Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 8/05/2024
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:AKYA
• CUSIP: N/A
• CIK: 1711933
• Web: www.akoyabio.com
• Phone: 855-896-8401
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.43
• High Stock Price Target: $10.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +151.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.38
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-63,320,000.00
• Net Margins: -66.77%
• Pretax Margin: -66.62%
• Return on Equity: -162.99%
• Return on Assets: -32.76%

Debt

• Debt-to-Equity Ratio: 5.62
• Current Ratio: 2.75
• Quick Ratio: 1.85

Sales & Book Value

• Annual Sales: $86.82 million
• Price / Sales: 1.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.10 per share
• Price / Book: 1.96

Miscellaneous

• Outstanding Shares: 49,563,000
• Free Float: 45,945,000
• Market Cap: $107.06 million
• Optionable: Optionable
• Beta: 1.34